Asymchem is awarded as “2018 Best Partner of China Pharmaceutical Enterprises in Transformation and Upgrading”

The 2019 China Pharma New Year Forecast was successfully held in Beijing by the Healthcare Executive and China Healthcare Industry Investment Forum, supported by the China Pharmaceutical Enterprises Association on January 19.

Many pharmaceutical policies were released in 2018. It was reported that 442 pharmaceutical policies were issued in January-May followed by other numerous polices in the second half of the year. The meeting presented topics in the following areas from the perspective of associations, enterprises and media: “Bulk purchasing in 4+7 cities”, “Innovative drug progress and business model”, “List of Essential Medicines”, “Pharmaceutical marketing compliance”, “Production process change”, “API monopoly”, “New retail, new terminal”, “Innovative integration of capital market and biological medicine”, and “State-funded medicines”. The think tank and insiders of the industry, together with nearly 500 entrepreneurs, scientists, and investors, were invited to discuss the trends of the pharmaceutical industry.

The candidates of the award were evaluated on various aspects, including insights in discovering clients’ needs for upgrading, the value of products and services and differential advantages, and customer feedback. Asymchem stood out as the only CDMO of the 6 award winners for the second time.

As a technology-driven word-leading CDMO, Asymchem has been committed to the innovation and application of pharmaceutical technologies for 20 years. Asymchem provides R&D and one-stop CMC services for major pharmaceutical enterprises and biotech enterprises at home and abroad. Asymchem carries out the R&D and production of innovative drugs and blockbuster drugs in strict accordance with cGMP requirements. Business scope covers pre-clinical studies of new drugs, process research and preparation, process optimization, and mass production of launched drugs in commercial phase.

With high barriers to business and leading innovative technologies, Asymchem has expanded its business scope from cGMP advanced intermediates and APIs to formulation. Asymchem has established cooperation with Merck, Pfizer, BMS, Abbvie, Lilly and other world-renowned enterprises and biotech companies. Asymchem has also established strategic partnerships with famous CROs and leading companies in the innovative industry chain worldwide to expand into clinical CRO and biologics, with an aim to improve the integrated service ecosystem of innovative drugs.  

Propelled with the desire for green and innovative development, Asymchem will continue to provide excellent efficient service for clients and make greater efforts to elevate the pharmaceutical industry.